Why Farbe Firma is the Top Manufacturer of Fluphenazine Decanoate Injection
- Maulik Sudani
- Jun 3
- 7 min read
Last Updated: June 3, 2026
TL;DR: Fluphenazine Decanoate Injection — a sterile oily depot solution of the long-acting phenothiazine antipsychotic fluphenazine decanoate, supplied most commonly as a 25 mg/mL solution in a sesame-oil or other oily vehicle in 1 mL and 10 mL ampoules and vials for deep intramuscular injection — is a cornerstone of maintenance treatment for schizophrenia and other chronic psychotic disorders. As a decanoate ester dissolved in an oily vehicle, it is slowly hydrolysed and released over two to four weeks, giving sustained dopamine D2-receptor blockade that supports adherence in patients for whom daily oral therapy is difficult. Because it is a non-aqueous, viscous, light-sensitive depot, its safety depends on exact ester assay, a controlled impurity and oxidation profile, water-free formulation, terminal-sterilisation or validated aseptic processing of an oily medium, and robust ampoule container-closure integrity. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Fluphenazine Decanoate Injection at our Gujarat, India facility and supplies it to hospital pharmacy, psychiatry and community-mental-health services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Long-acting (depot) phenothiazine antipsychotic — Fluphenazine Decanoate Injection is used for the maintenance treatment of schizophrenia and other chronic psychoses, providing sustained dopamine D2-receptor blockade as the decanoate ester is slowly hydrolysed and released from an oily depot over two to four weeks to support adherence.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection and oily-vehicle handling, qualified ampoule and vial filling lines for a viscous non-aqueous depot, dedicated control of ester assay, the oxidation and impurity profile, particulate and endotoxin, with container-closure integrity verification and protection from light on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations including ministry-of-health, psychiatry-formulary and hospital tenders.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready ampoule and vial packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Fluphenazine Decanoate Injection Demands a Premium Manufacturer
Fluphenazine Decanoate Injection occupies an important place in long-term psychiatric care. It is a long-acting depot antipsychotic that psychiatrists and community-mental-health teams depend on for the maintenance treatment of schizophrenia and other chronic psychotic illnesses, particularly where adherence to daily oral medication is difficult. Given by deep intramuscular injection once every two to four weeks, the decanoate ester is slowly released from its oily vehicle and hydrolysed to active fluphenazine, providing steady dopamine D2-receptor blockade that reduces relapse and re-hospitalisation. In this setting the patient depends on a depot dose that is delivered accurately and releases predictably over the full dosing interval, so each ampoule must contain an exact, reproducible amount of the ester in a stable oily medium.
That clinical reality places real demands on the manufacturer. Fluphenazine decanoate is a lipophilic ester formulated not in water but in a sterile oily vehicle such as sesame oil, and a non-aqueous depot carries its own discipline that aqueous injections do not. The ester assay must be exact and held across a long shelf life; the oxidation and impurity profile of both the ester and the oil must be controlled, because phenothiazines and unsaturated oils are prone to light- and oxygen-driven degradation; the product must be effectively water-free; and an oily medium cannot always be sterile-filtered conventionally, so the process relies on validated terminal sterilisation or rigorous aseptic processing with careful viscosity control during filling. The viscous solution must still fill accurately into ampoules that are reliably fusion-sealed and verified for container-closure integrity. Choosing a Fluphenazine Decanoate Injection manufacturer that treats ester assay, oxidation control, water-free formulation, sterilisation of an oily medium and ampoule integrity as core engineering disciplines is what protects the patient on maintenance therapy.
What Sets a World-Class Fluphenazine Decanoate Injection Manufacturer Apart
A world-class manufacturer of Fluphenazine Decanoate Injection invests in three areas that weaker suppliers underfund: an exact, stability-indicating assay of the decanoate ester together with tight control of its oxidation and impurity profile by HPLC for a light-sensitive phenothiazine, validated sterilisation and accurate filling of a viscous, non-aqueous oily depot with verified container-closure integrity, and tender-ready dossier support for a product procured largely through psychiatry-formulary, community-mental-health and ministry-of-health channels. It starts with the active — pharmacopoeial-grade fluphenazine decanoate and a qualified pharmaceutical-grade oily vehicle (such as sesame oil meeting USP/BP/IP/EP standards), sourced from qualified, audited makers, with full assay, peroxide-value and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Formulation, filling and sealing then have to preserve both the assay and the dose in an oily medium. The ester is dissolved in the qualified, low-peroxide oily vehicle under controlled, often inert (nitrogen-blanketed) conditions to limit oxidation, with the option of a small antioxidant where the monograph permits. Because the vehicle is non-aqueous and viscous, the product is sterilised by a validated terminal process or filled by rigorous aseptic technique, then filled aseptically into clear- or amber-glass ampoules and vials under ISO Class 5 air with viscosity-compensated dosing for accurate fill volume. Each ampoule is fusion-sealed and 100 % inspected for particulate matter, fill volume, seal quality and cosmetic defects; in-process and release testing confirm ester assay by HPLC, the oxidation and impurity profile, the appearance and viscosity of the oily solution, and container-closure integrity is verified by dye-ingress or vacuum testing so that every sealed unit protects the patient.
Quality Systems Behind Every Fluphenazine Decanoate Injection
Every Farbe Firma Fluphenazine Decanoate Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of fluphenazine decanoate against USP, BP, IP or EP reference standards, control of related substances and oxidation products by HPLC, peroxide value and identity of the oily vehicle, appearance, colour and viscosity of the oily solution, water content by Karl Fischer to confirm the product is effectively anhydrous, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration or direct inoculation as appropriate for an oil, fill-volume verification and container-closure integrity for the 1 mL and 10 mL ampoule and vial formats. Certificates of analysis are issued with full traceability back to the API lot, the oily-vehicle lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection and oily-vehicle handling systems, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated ampoule and vial filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because the product is a light- and oxygen-sensitive non-aqueous depot whose ester assay and oxidation profile drive both efficacy and shelf life, we treat the stability-indicating HPLC assay and the oxidation-product result as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and the product is protected from light and oxygen through its primary and secondary packaging.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Fluphenazine Decanoate Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across psychiatry, neurology, anti-infective, critical-care and supportive-care categories. For Fluphenazine Decanoate Injection specifically, we supply a 25 mg/mL oily depot solution in 1 mL and 10 mL ampoules and vials under WHO-GMP conditions, with country-specific strengths, fill volumes and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the ester-assay, oxidation-profile and stability data package — ready to hand for registration.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics. When a buyer needs Fluphenazine Decanoate Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, oily-depot filling-line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the oily-depot suite; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API and oily-vehicle sourcing, stability-indicating assay development, oxidation and impurity control, sterilisation of a non-aqueous medium, ampoule container-closure integrity, photostability and shelf-life choices in real detail. For a long-acting depot antipsychotic given for maintenance of chronic psychosis, where ester assay, predictable release and ampoule integrity directly govern relapse prevention and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Fluphenazine Decanoate Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Fluphenazine Decanoate Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified oily-depot ampoule and vial filling lines, qualified water-for-injection and oily-vehicle handling systems, 100 % ampoule inspection and continuous environmental monitoring.
Which strengths and pack sizes of Fluphenazine Decanoate Injection do you supply?
Our standard presentation is a 25 mg/mL oily depot solution (fluphenazine decanoate in a pharmaceutical-grade oily vehicle) in 1 mL and 10 mL clear- or amber-glass ampoules and vials. Custom strengths, fill volumes, unit counts per pack and country-specific artwork are available under contract manufacturing agreements.
Can Farbe Firma support country-specific registrations for Fluphenazine Decanoate Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
How does Farbe Firma assure the quality and safety of Fluphenazine Decanoate Injection?
We control the ester assay and related substances by stability-indicating HPLC against pharmacopoeial standards, verify the peroxide value and identity of the oily vehicle, confirm the product is effectively anhydrous by Karl Fischer, check appearance, colour and viscosity, hold endotoxin well within limits by LAL, run particulate and sterility testing, 100 %-inspect every ampoule, verify container-closure integrity by dye-ingress or vacuum testing, protect the product from light and oxygen, and qualify each batch against ICH Q1A and ICH Q1B protocols.
What is the minimum order quantity for Fluphenazine Decanoate Injection contract manufacturing?
MOQs vary by ampoule or vial size, fill volume, label complexity and dossier requirements. For the 1 mL and 10 mL presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments